{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Deep Medicine Acquisition Corp.
Is Deep Medicine Acquisition Corp. overvalued or undervalued?
As of May 10, 2024, Deep Medicine Acquisition Corp. is rated as risky due to its negative P/E ratio, a Price to Book Value of -1.36, and an EV to EBITDA ratio of -5.76, indicating overvaluation and financial distress despite a strong year-to-date return of 384.06%, which is unsustainable compared to the S&P 500's 12.22% return.
Is Deep Medicine Acquisition Corp. overvalued or undervalued?
As of May 10, 2024, Deep Medicine Acquisition Corp. is rated as risky and overvalued, with key financial ratios indicating a lack of profitability and negative capital employed, despite a recent unsustainable stock return of 3002.11%.
Is Deep Medicine Acquisition Corp. technically bullish or bearish?
As of June 20, 2025, the trend is mildly bearish due to daily moving averages, despite some bullish signals from the weekly MACD and Bollinger Bands, indicating mixed momentum and uncertainty.
What does Deep Medicine Acquisition Corp. do?
Deep Medicine Acquisition Corp. is a micro-cap finance company with recent net sales of $5 million and a net loss of $3 million. It has a market cap of $4.61 million and does not pay dividends.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
